You are on page 1of 2

GMP News 27/01/2011

Laboratory Control Issues Prominent in Recent Warning Letters to Four Overseas Firms
Laboratory control problems are prominent in a bolus of FDA drug GMP warning letters recently issued to companies in Asia and Europe. In mid-October, the agency posted letters it had recently issued to two active pharmaceutical ingredient (API) firms in China and Japan, respectively, to a contract testing laboratory in India and to a contract tablet and powder manufacturer in Belgium - all of which reference deficiencies in lab practice. The four warning letters also showcase the growing emphasis FDA investigators are placing on the quality assurance linkages between the participants involved in the supply chain. The API manufacturers receiving the letters were Hofu City, Japan-based Kyowa Hakko Kogyo and Shulan City, China-based Jilin Shulan Synthetic Pharmaceutical. The letter went out to Kyowa in late September referencing a June inspection and to Jilin in May addressing findings during a late-August 2009 inspection. Warning letters went out to Hyryana, India-based Choksi Laboratories and Qualiphar in Bornem, Belgium at the end of September - both referencing findings from inspections in the late Aprilearly May timeframe. In line with FDA procedures, the four foreign warning letters were issued by the Division of Manufacturing and Product Quality (DMPQ) in the Center for Drug Evaluation and Research (CDER) Office of Compliance and signed by DMPQ Director Richard Friedman. The prominence of laboratory control issues in the four letters reflects their overall frequency in 483s issued to foreign firms, according to recent FDA data.

adding that "the documentation challenge is significant in my experience" in working with Chinese firms. who led CDER's Division of Manufacturing and Product Quality before leaving the agency in the mid-1990s. Industry consultant Paul Vogel. Inadequate lab controls was a little less frequently cited area in India. Maryland on October 20-21." he suggested. He was surprised. that SOPs were not cited more frequently in China. Deficiencies in buildings/facilities and in records/reports were a distant second. running second at 9% to problems in QA systems (16%). . comprising almost one in four (23%) of the GMP deviations included in 483s issued to Chinese firms in FY 2010. In Europe. "The primary reason could be the difficulty posed by the language barrier to really assess the adequacy or inadequacy of the procedures and quality systems themselves. Lab problems were particularly prominent in China." in Bethesda. Vogel noted that he was not surprised that lab controls along with QC responsibilities were the leading GMP citations. followed by QA systems (11%) and lack of or inadequate SOPs (10%). Lack of or inadequate SOPs was the second most frequent 483 citation internationally at 10% of the total. inadequate lab controls made up 13% of the drug GMP citations. with 7% of the citations each. making up over one in seven (15%) of all 483 listings. reviewed the recent FDA foreign inspection findings at the annual Generic Pharmaceutical Association/FDA "Fall Technical Conference. however.Inadequate lab controls were the top agency drug GMP citation area abroad in FY 2010 (ending September 30). as they have been among the top concerns for some time.